ZymoGenetics licenses recombinant protein to Novo Nordisk

10/5/2004 | Forbes · Seattle Times, The

The deal gives Novo Nordisk exclusive worldwide rights to rFactor XIII, a genetically engineered blood-clotting protein, and any products related to it. ZymoGenetics stands to gain more than $77 million as a result of the agreement and plans to concentrate on three other drugs it considers more profitable.

View Full Article in:

Forbes · Seattle Times, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC